Why Big Pharma Is Backing a €65M RNA Loop

Norwegian biotech Circio raises €65M in a major Series C round to push its proprietary circular RNA platform into clinical trials

26 Jun 2026

The standard molecular recipe for modern medicine relies on linear strands of messenger RNA. Yet these strands are fragile things, prone to degrading inside the human body before they can deliver their therapeutic instructions. By twisting these straight lines into loops, biotechnology firms hope to create a more durable class of medicine.

In April 2026, Circio, a Norwegian biotech firm, closed an oversubscribed €65m ($70m) Series C funding round. The cash injection represents a significant vote of confidence in its proprietary platform, circVec, which designs circular RNA molecules. More notable than the money itself is the identity of its backer: an unnamed top-five pharmaceutical giant that has committed to a fully funded gene therapy collaboration. For a sector often bloated by unproven promises, this corporate endorsement provides rare, early-stage credibility.

The enthusiasm stems from basic biology. Circular RNA resists the cellular enzymes that typically chew up linear RNA, offering greater stability and longer-lasting therapeutic effects. If the technology works, it could drastically compress drug development timelines and open new pathways for treating rare diseases and oncology.

However, moving from pre-clinical promise to human reality is notoriously difficult. The history of biotechnology is littered with platforms that functioned beautifully in petri dishes but failed in patients. Circio’s fresh capital will be used to push its platform into early-stage clinical trials.

For Europe’s biotech ecosystem, which frequently lags behind America in venture funding, Circio is a welcome flagship. But the real test lies ahead. The firm must now generate human data to prove that its molecular loops can deliver real clinical results, rather than just spinning investor wheels.